Alan K. Matsumoto

1.0k total citations
18 papers, 675 citations indexed

About

Alan K. Matsumoto is a scholar working on Rheumatology, Pharmacology and Immunology. According to data from OpenAlex, Alan K. Matsumoto has authored 18 papers receiving a total of 675 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Rheumatology, 6 papers in Pharmacology and 4 papers in Immunology. Recurrent topics in Alan K. Matsumoto's work include Rheumatoid Arthritis Research and Therapies (7 papers), Inflammatory mediators and NSAID effects (5 papers) and Biosimilars and Bioanalytical Methods (3 papers). Alan K. Matsumoto is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (7 papers), Inflammatory mediators and NSAID effects (5 papers) and Biosimilars and Bioanalytical Methods (3 papers). Alan K. Matsumoto collaborates with scholars based in United States, United Kingdom and Germany. Alan K. Matsumoto's co-authors include Najib Babul, Harry Ahdieh, Joan M. Bathon, Stanley Cohen, Andrew Bilderback, Susan J. Bartlett, Ralph L. Piedmont, Karel Pavelká, José L. Pablos and Mark C. Genovese and has published in prestigious journals such as Journal of the American Geriatrics Society, Annals of the Rheumatic Diseases and Arthritis Research & Therapy.

In The Last Decade

Alan K. Matsumoto

17 papers receiving 639 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alan K. Matsumoto United States 13 199 196 192 85 80 18 675
H. A. Bird United Kingdom 18 183 0.9× 83 0.4× 308 1.6× 16 0.2× 65 0.8× 58 793
Alejandro Arana United States 16 75 0.4× 59 0.3× 63 0.3× 7 0.1× 106 1.3× 37 1.2k
Ian Kronborg Australia 18 84 0.4× 71 0.4× 15 0.1× 48 0.6× 315 3.9× 27 1.1k
Jiat Ling Poon United States 19 97 0.5× 49 0.3× 28 0.1× 9 0.1× 59 0.7× 73 974
Ruth Bolier Netherlands 12 80 0.4× 48 0.2× 49 0.3× 30 0.4× 50 0.6× 17 744
Ravi Potluri United States 13 108 0.5× 24 0.1× 45 0.2× 8 0.1× 79 1.0× 77 774
Anita Chopra India 17 49 0.2× 93 0.5× 22 0.1× 8 0.1× 81 1.0× 132 1.1k
Yvonne E. Yarker United States 6 37 0.2× 11 0.1× 158 0.8× 24 0.3× 124 1.6× 8 693
Donald B. Wender United States 14 45 0.2× 25 0.1× 30 0.2× 35 0.4× 327 4.1× 31 1.1k
Markay Hopps United States 13 127 0.6× 9 0.0× 56 0.3× 38 0.4× 253 3.2× 22 753

Countries citing papers authored by Alan K. Matsumoto

Since Specialization
Citations

This map shows the geographic impact of Alan K. Matsumoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan K. Matsumoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan K. Matsumoto more than expected).

Fields of papers citing papers by Alan K. Matsumoto

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan K. Matsumoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan K. Matsumoto. The network helps show where Alan K. Matsumoto may publish in the future.

Co-authorship network of co-authors of Alan K. Matsumoto

This figure shows the co-authorship network connecting the top 25 collaborators of Alan K. Matsumoto. A scholar is included among the top collaborators of Alan K. Matsumoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan K. Matsumoto. Alan K. Matsumoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
2.
Baker, Matthew, Sarah Kavanagh, Stanley Cohen, et al.. (2023). A Randomized, Double‐Blind, Sham‐Controlled, Clinical Trial of Auricular Vagus Nerve Stimulation for the Treatment of Active Rheumatoid Arthritis. Arthritis & Rheumatology. 75(12). 2107–2115. 14 indexed citations
3.
Aletaha, Daniel, René Westhovens, C. Gaujoux-Viala, et al.. (2021). Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3. RMD Open. 7(2). e001621–e001621. 14 indexed citations
4.
Cohen, Stanley, José L. Pablos, Karel Pavelká, et al.. (2019). An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis. Arthritis Research & Therapy. 21(1). 84–84. 27 indexed citations
5.
Cohen, Stanley, Mark C. Genovese, Ernest Choy, et al.. (2017). Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. Annals of the Rheumatic Diseases. 76(10). 1679–1687. 135 indexed citations
6.
Baraf, Herbert S. B. & Alan K. Matsumoto. (2012). Pegloticase: a new biologic for treating advanced gout. International Journal of Clinical Rheumatology. 7(2). 143–154. 2 indexed citations
7.
Baraf, Herbert S. B., Alan K. Matsumoto, Allan N. Maroli, & Royce W. Waltrip. (2008). Resolution of gouty tophi after twelve weeks of pegloticase treatment. Arthritis & Rheumatism. 58(11). 3632–3634. 37 indexed citations
8.
Matsumoto, Alan K., Agustin Melian, Arvind Shah, & Sean Curtis. (2007). Etoricoxib versus naproxen in patients with rheumatoid arthritis: a prospective, randomized, comparator-controlled 121-week trial. Current Medical Research and Opinion. 23(9). 2259–2268. 8 indexed citations
9.
Matsumoto, Alan K.. (2007). Oral extended-release oxymorphone: a new choice for chronic pain relief. Expert Opinion on Pharmacotherapy. 8(10). 1515–1527. 14 indexed citations
10.
11.
Battisti, Wendy P., Nathaniel P. Katz, Arthur L. Weaver, et al.. (2004). Pain management in osteoarthritis: A focus on onset of efficacy—a comparison of rofecoxib, celecoxib, acetaminophen, and nabumetone across four clinical trials. Journal of Pain. 5(9). 511–520. 29 indexed citations
12.
Kivitz, Alan, Maria Greenwald, Stanley Cohen, et al.. (2004). Efficacy and Safety of Rofecoxib 12.5 mg Versus Nabumetone 1,000 mg in Patients with Osteoarthritis of the Knee: A Randomized Controlled Trial. Journal of the American Geriatrics Society. 52(5). 666–674. 27 indexed citations
13.
Matsumoto, Alan K. & Paul F. Cavanaugh. (2004). Etoricoxib.. PubMed. 40(5). 395–414. 11 indexed citations
14.
Bartlett, Susan J., Ralph L. Piedmont, Andrew Bilderback, Alan K. Matsumoto, & Joan M. Bathon. (2003). Spirituality, well‐being, and quality of life in people with rheumatoid arthritis. Arthritis Care & Research. 49(6). 778–783. 85 indexed citations
15.
Matsumoto, Alan K., David R. Mandel, Harris McIlwain, et al.. (2002). A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis.. PubMed. 29(8). 1623–30. 99 indexed citations
16.
Matsumoto, Alan K., Robert G. Moore, Patricia M. Alli, & Frederick M. Wigley. (2000). Three cases of osteonecrosis of the lunate bone of the wrist in scleroderma.. PubMed. 17(6). 730–2. 17 indexed citations
17.
Moreland, Larry W., Elizabeth E. Morgan, T. C. Adamson, et al.. (1998). T cell receptor peptide vaccination in rheumatoid arthritis: A placebo-controlled trial using a combination of V?3, V?14, and V?17 Peptides. Arthritis & Rheumatism. 41(11). 1919–1929. 57 indexed citations
18.
Moreland, Larry W., Elizabeth E. Morgan, T. C. Adamson, et al.. (1998). T cell receptor peptide vaccination in rheumatoid arthritis: A placebo-controlled trial using a combination of V3, V14, and V17 Peptides. Arthritis & Rheumatism. 41(11). 1919–1929. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by H. A. Bird Breakdown of academic impact, for papers by Alejandro Arana Breakdown of academic impact, for papers by Ian Kronborg Breakdown of academic impact, for papers by Jiat Ling Poon Breakdown of academic impact, for papers by Ruth Bolier Breakdown of academic impact, for papers by Ravi Potluri Breakdown of academic impact, for papers by Anita Chopra Breakdown of academic impact, for papers by Yvonne E. Yarker Breakdown of academic impact, for papers by Donald B. Wender Breakdown of academic impact, for papers by Markay Hopps
Rankless by CCL
2026